Biolojic Design, Ltd.

Today, we announced the appointment of Neal Curran as our Chief Business Officer. Neal has extensive experience in business development in the biopharmaceutical industry, including 18 years GSK, where he most recently served as Vice President, Human Genetics Business Development. Neal will support the expansion of our U.S. presence, helping us take the next step in our evolution as a global biotechnology company. Welcome Neal! Learn more: https://bit.ly/4ggxNjd

We’re proud to announce that we’ve joined Johnson & Johnson JLABS @ Washington, D.C.    We believe that our expansion in the United States will enable us to accelerate our ability to develop our pipeline of candidates in immunology and oncology, and to get these programs to patients.   Learn more: https://bit.ly/3OAPsGx   #JLABS #CapitalRegion #Biotechnology

Tonight’s the night! We’ll find out if our collaboration with Merck KGaA, Darmstadt, Germany is selected as the Deal of the Year (deal volume below €500 million) at the European Lifestars Awards! We’re excited for the event, and even more enthusiastic about the potential of this partnership to generate best-in-class treatments for patients with cancer and immunological disorders. Wish us luck! #lifestarsawards

Do you want to learn more about how Biolojic Design, Ltd. is using artificial intelligence to create programmable antibodies and how they differ from traditional antibodies?   On The Pharma Letter podcast, our CEO and Founder Yanay Ofran discusses our science and programs, and what lies ahead for Biolojic Design.    #Antibodies #AI #Biotechnology

Great article in Drug Target Review featuring our CEO, Yanay Ofran. He discusses how we are redefining antibody therapies by creating programmable molecules that can adjust their activity based on their biological environment, with the goal of creating safer and more effective new medicines: https://bit.ly/3ZS0nCt

We’re thrilled that our collaboration with Merck KGaA, Darmstadt, Germany is a finalist for the Deal of the Year (deal volume below €500 million) at the European Lifestars Awards!   This category recognizes “teams and organizations who have executed a truly transformational and high value creating deal.” We are excited about the potential of this partnership to generate best-in-class treatments for patients with cancer and immunological disorders and honored for the recognition of its promise.   We’re looking forward to the announcement of the winner on November 18.   #lifestarsawards

We’re excited to announce our collaboration with Merck KGaA, Darmstadt, Germany. Our teams will be leveraging our clinically validated, AI-driven platform to design potential best-in-class multi-specific antibodies for the treatment of cancer and immunological diseases, including antibody-drug conjugates (ADCs) against novel therapeutic targets. You can read more about our collaboration here: https://bit.ly/4e3tHKT. EMD Serono, Inc. #AI #drugdiscovery #ADCs #Oncology #Immunology

We’re excited to announce our collaboration with Merck KGaA, Darmstadt, Germany. Our teams will be leveraging our clinically validated, AI-driven platform to design potential best-in-class multi-specific antibodies for the treatment of cancer and immunological diseases, including antibody-drug conjugates (ADCs) against novel therapeutic targets. You can read more about our collaboration here: https://bit.ly/4e3tHKT. EMD Serono, Inc. #AI #drugdiscovery #ADCs #Oncology #Immunology

Today we announced that our partner Nektar Therapeutics has exercised its license option to develop our AI-designed antibody targeting TNFR2 (now NKTR-0165) for the treatment of autoimmune diseases such as ulcerative colitis, multiple sclerosis and vitiligo. Nektar expects to advance NKTR-0165 through IND-enabling studies in 2024, with the goal of filing an IND in the first half of 2025. You can read more here: bit.ly/3w50Rso

This morning in print in TheMarker (Hebrew):